RNAC · Cartesian Therapeutics Inc
United States · RS rating 29 · As of 2026-11-03
| Price | 6.41 USD |
|---|---|
| 1-day change | +1.1% |
| RS rating (overall / 1M / 3M / 12M) | 29 / 35 / 27 / 36 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 33 / 21 / 36 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +131.5% |
| Sales growth Q/Q | +109.5% |
| Distance from 52-week high | +39.5% |
| Market cap (USD) | $184.8M |